Richard Dillon

@DillonHaem

Haemato-oncology / Acute Myeloid Leukaemia / Molecular Acrobatics. @gsttnhs @kingsmedicine

SE1 9RT Joined January 2019

1.3K Following 1.3K Followers 94 Posts

Latest posts 5

Richard Dillon @DillonHaem Oct 6, 2023

Dream Job Opportunity ! Academic Clinical Fellowship in Haematology (Guy's, King's, UCLH and Barts available) please contact me if interested in the Guy's / Kings one. oriel.nhs.uk/Web/PermaLink/…

Richard Dillon @DillonHaem Feb 10, 2023

Congratulations to @WillVilliers on his first born paper, i'm sure its the first of many.

Cameron Osborne @CamOsbornelab Feb 10, 2023

Well done to @WillVilliers and everyone involved for our new machine learning/multi-omics paper in @NatureComms.
nature.com/articles/s4146…

👇Here’s a recap:
View quoted post on X

Richard Dillon @DillonHaem Aug 17, 2022

Ultra sensitive detection of FLT3-ITD: a novel and powerful MRD marker - and one that could potentially be used to guide molecularly targeted interventions. Read all about it here!

ashpublications.org/blood/article/…

ashpublications.org Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical... TO THE EDITOR:

Richard Dillon @DillonHaem Dec 7, 2021

Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia - Further results from the UK NCRI AML17 trial in collaboration with Australian colleagues. Hope you enjoy :-) sciencedirect.com/science/articl…

Richard Dillon @DillonHaem Jun 9, 2021

bloodcancer.org.uk/research/resea…

bloodcancer.org.uk Blood Cancer UK | Reducing the need for chemotherapy in people with acute myeloid leukaemia (AML) Dr Charlotte Graham's clinical trial is testing a new type of CAR-T cell therapy to find a new way to treat myeloma.